Keytruda’s fast track designation is based on encouraging results from the Phase II/III IND.227/KEYNOTE-483 trial, which showed improved overall survival for patients with unresectable advanced or metastatic malignant pleural mesothelioma.
FDA grants Priority Review to Keytruda combination therapy for first-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma
Leave a Comment
